Olmesartan Medoxomil Msn Laboratories Europe

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Msn Laboratories Europe, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Olmesartan Medoxil Msn Laboratories Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxil Msn Laboratories Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxil is an angiotensin‑II receptor antagonist indicated for conditions affecting the renin‑angiotensin system.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhoea - Cough

Serious or Rare Side Effects: - Angio‑ema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Bullous pemphigoid - Myocardial infarction

When prescribing Olmesartan medoxil, clinicians should consider several safety aspects.

- Monitor renal function: assess serum creatinine and eGFR before initiation and periodically thereafter. - Check electrolytes: watch for hyper‑kalaemia, especially in patients on potassium‑sparing diuretics. - Avoid in pregnancy:   - Contraindicated   - Use   - Store at  :  

Olmes-­  

Major  

   t